IRF4 Positivity is a Novel Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

被引：0
|
作者：
Cakir, F. B. [1 ]
Guler, B. [2 ]
Cay, A. [3 ]
Mirapoglu, S. [3 ]
Turkmen, A. Vehaboglu [4 ]
Aki, H. [5 ]
机构：
[1] Bezmialem Vakif Univ, Pediat Hematol Oncol, Istanbul, Turkey
[2] Bezmialem Vakif Univ, Pathol, Istanbul, Turkey
[3] Bezmialem Vakif Univ, Pediat Surg, Istanbul, Turkey
[4] Bezmialem Vakif Univ, Pediat, Istanbul, Turkey
[5] Istanbul Univ, Pathol, Cerrahpasa Med Fac, Istanbul, Turkey
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-228
引用
收藏
页码：S196 / S196
页数：1
相关论文
共 50 条
  • [31] MHC class II loss in diffuse large B-cell lymphoma is inversely correlated with MUM1/IRF4 expression
    Wilkinson, Sarah
    Fernandez, Diane
    Chan, Wing
    Gascoyne, Randy
    Campo, Elias
    Jaffe, Elaine
    Staudt, Louis
    Delabie, Jan
    Rosenwald, Andreas
    Rimsza, Lisa
    CANCER RESEARCH, 2009, 69
  • [32] B cell lymphoma with IRF4 rearrangement: A clinicopathological study of 13 cases
    Zhou, Luting
    Gu, Bin
    Shen, Xia
    Binshen, Ouyang
    Dong, Lei
    Zhou, Jun
    Yi, Hongmei
    Wang, Chaofu
    PATHOLOGY INTERNATIONAL, 2021, 71 (03) : 183 - 190
  • [33] Novel prognostic scoring system for diffuse large B-cell lymphoma
    Zhao, Pan
    Zang, Li
    Zhang, Xiaoying
    Chen, Yafang
    Yue, Zhijie
    Yang, Hongliang
    Zhao, Haifeng
    Yu, Yong
    Wang, Yafei
    Zhao, Zhigang
    Zhang, Yizhuo
    Wang, Xiaofang
    ONCOLOGY LETTERS, 2018, 15 (04) : 5325 - 5332
  • [34] Super-enhancer analysis defines IRF4 as a target in anaplastic large cell lymphoma and rational design of IRF4 degrader molecules
    Giordano, C.
    Prutsch, N.
    Gurnhofer, E.
    Aplenc, A.
    Kenner, L.
    Look, A. T.
    Touaibia, M.
    Merkel, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 264 - 264
  • [35] Molecular analyses of pediatric type follicular lymphoma and large B cell lymphoma with IRF4 translocation in children and young adolescents
    Hawkins, Cynthia
    Kowalski, Paul
    Ngan, Bo-Yee
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 85 - 85
  • [36] CD5+Large B cell lymphoma with IRF4 rearrangement: case report and review of the literature
    Torres, Y.
    Shen, P.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S76 - S76
  • [37] IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in children's oncology group trials
    Chisholm, Karen M.
    Mohlman, Jeffrey
    Liew, Michael
    Termuhlen, Amanda
    Cairo, Mitchell S.
    Gross, Thomas G.
    Perkins, Sherrie L.
    Miles, Rodney R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 81 - 81
  • [38] Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma
    Fei Xiong
    Guan-Hua Wu
    Bing Wang
    Yong-Jun Chen
    Cancer Cell International, 21
  • [39] Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma
    Xiong, Fei
    Wu, Guan-Hua
    Wang, Bing
    Chen, Yong-Jun
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [40] IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials
    Chisholm, Karen M.
    Mohlman, Jeffrey
    Liew, Michael
    Termuhlen, Amanda
    Cairo, Mitchell S.
    Gross, Thomas G.
    Perkins, Sherrie L.
    Miles, Rodney R.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (08)
12345